PCSK9 gene participates in the development of primary dyslipidemias
Dyslipidemias are a group of diseases, which are characterized by abnormal blood concentrations of cholesterol, triglycerides and/or low-density lipoprotein-cholesterol (LDL-c). Dyslipidemia is a determinant condition for the progress of an atherosclerotic plaque formation. The resulting atherogenic...
Main Authors: | Matías-Pérez D, Pérez-Santiago AD, Sánchez Medina MA, Alpuche Osorno JJ, García-Montalvo IA |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2021-07-01
|
Series: | Balkan Journal of Medical Genetics |
Subjects: | |
Online Access: | https://doi.org/10.2478/bjmg-2021-0009 |
Similar Items
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01) -
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
by: Yue-Wei Qian, et al.
Published: (2007-07-01) -
Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells
by: Gan S, et al.
Published: (2017-04-01) -
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01) -
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
by: Yuki Awanami, et al.
Published: (2017-07-01)